Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs as well as shares acquired through the company’s Employee Stock Purchase Plan. For deeper insights into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro. For deeper insights into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs as well as shares acquired through the company’s Employee Stock Purchase Plan. For deeper insights into Liquidia’s valuation metrics and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
Following this sale, Saggar holds 267,943 shares of Liquidia Corp, including a mix of vested and unvested RSUs as well as shares acquired through the company’s Employee Stock Purchase Plan.
In other recent news, Liquidia Corporation reported a rise in Q3 revenue to $4.4 million, up from $3.7 million in the same quarter of the previous year. The company, however, reported a net loss of $23.2 million. The corporation is preparing for the potential launch of their inhaled treatment YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease post the expiration of TYVASO DPI’s exclusivity in May 2025. Liquidia is also advancing the development of its next-generation product L606, with a pivotal study set to begin in the first half of 2025. In addition, the company has expanded its partnership with Pharmosa for the development of a next-generation nebulizer. These are recent developments that highlight the company’s continued efforts to innovate in the healthcare field. Please note that the company’s financial health and strategic partnerships suggest a robust approach to meeting the needs of patients and healthcare providers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.